Atai Beckley Inc宣布,其研究性药物Emp-01在临床试验中展现出良好的安全性与耐受性特征。试验数据显示,未报告任何严重的或重度的不良事件,表明该药物的安全性符合预期。
Atai Beckley Inc宣布,其研究性药物Emp-01在临床试验中展现出良好的安全性与耐受性特征。试验数据显示,未报告任何严重的或重度的不良事件,表明该药物的安全性符合预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.